SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

Traders are focused on Bankrs AI-agent and crypto-trading infrastructure, citing ecosystem integrations, reported protocol revenue, and fee-linked buybacks as reasons for long-term optimism. The conversation is also driven by recent price movement, with dip-buying and accumulation alongside concerns about volatility and whether the projects fundamentals will translate into sustained demand.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

A sharp selloff has prompted speculation about a possible reverse split or share buyback, but neither is confirmed in the discussion; traders are divided between warning of further downside and viewing the pullback as an opportunity ahead of Almontys investor day and Sangdongs production ramp.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Q3 results are driving discussion: Schwab beat earnings expectations and reported strong asset gathering, but a slight revenue miss, slower sequential growth and softer trading revenue weighed on the shares. Traders are split between viewing the quarters underlying growth as strong and questioning whether the results justify a more positive market reaction.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVies run to new highs is drawing attention amid a broader rotation into defensive healthcare stocks as technology shares weaken, with traders highlighting the stocks breakout momentum and pipeline progress. Some see room for the rally to continue, while others warn it may be overextended and expect a pullback.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluences sharp selloff is centered on another FY2026 guidance cut tied to delays ramping its Houston contract-manufacturing facility, which traders say is keeping its backlog from converting into deliveries and revenue. The dominant debate is whether strong energy-storage demand and the new COO can support a turnaround, or whether repeated execution problems and lost management credibility will continue to weigh on the stock.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs sharp, extended selloff despite Bitcoin holding near elevated levels is driving discussion, with traders highlighting the stocks weak performance relative to BTC. Bears point to management concerns, dilution and the lack of signed AI/data-center tenants, while bulls see the decline as a buying opportunity and speculate about a short squeeze.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

OXY is drawing attention as traders link its recent strength and technical rebound to crude prices and Middle East supply-risk headlines, with some also pointing to Goldmans upgrade and the companys debt reduction. Sentiment is divided: bulls see support from oil-driven cash flow, while others note OXY has often lagged crude and could weaken if geopolitical tensions ease.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Discussion centers on Warren Buffetts leadership transition and whether Greg Abel can deploy Berkshires large cash reserves effectively, amid complaints that the shares have lagged the broader market. Bulls view Berkshires cash-rich, diversified business as a defensive refuge, while skeptics argue its cautious approach has left shareholders with weak returns.

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Acadia Pharmaceuticals Inc

Acadias shares are under pressure after its Alzheimers psychosis drug remlifanserin narrowly missed the Phase 2 RADIANT primary endpoint, despite a favorable safety profile and a positive secondary measure; the company plans to continue Phase 3 studies while removing the lower dose. Traders are split between viewing the result as a serious setback and treating the selloff as an oversold buying opportunity, with some focused on upcoming data details and others questioning the drugs prospects.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Traders are focused on the upcoming CTX310 Phase 1b data presentation at the AHA, alongside a zugo-cel update, as key clinical catalysts. The discussion weighs optimism about the pipeline against frustration over CRSPs recent decline and prolonged range-bound trading.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NVAX  Based on the news and data provided on deliveries and EU, Australia, NZ price leak,  seems like Novavax hit the $1 Billion sales/revenue for Q1.  If  there&#39;s 1 batch of 3.2 million doses for Canada and the UK this week, that moves revenue to around 1.15 Billion. Novavax also gets around $200M every quarter in 2021 for grants/royalties.  1st Quarter gross sales could be $1B - $1.3B in the May 9 Q1 report.

Paul Di

e0fknu2k

Ramón de la Vega

Delicious_Aloysius

Tim Chron

Jacked to the twits!

Jerry

Scoop

Moixet

Charging Bull

David G

Louie Gi

Alan

Truth Will Set You Free

Muskington

DarvasBoxing

William L Maltby

Twix

TopShelfStock

Wade

Jose David

Tony Wadie

Skiwp

Álvaro González

Armin Yukihura

Kevin Chan

Alex Johnson

John

Stian Bøhlerengen

Moyses Garcia

StockTwits Web

Novavax Inc

  Based on the news and data provided on deliveries and EU, Australia, NZ price leak,  seems like Novavax hit the $1 Billion sales/revenue for Q1.  If  there's 1 batch of 3.2 million doses for Canada and the UK this week, that moves revenue to around 1.15 Billion. Novavax also gets around $200M every quarter in 2021 for grants/royalties.  1st Quarter gross sales could be $1B - $1.3B in the May 9 Q1 report.

Al Y

@ay8888 thats a very optimistic price per dose because we don&#39;t know how much they are even paying SII for the doses

Keegan

Jo Wu

 thats a very optimistic price per dose because we don't know how much they are even paying SII for the doses

Diego Raul Gonzales Jr. III

@ay8888 Seems reasonable given the guidance NVAX provided that Q1 would approach or even surpass $1B in revenue.  The CFO commentary on COGS being incurred in Q4 bodes well that margins could benefit in Q1/Q2.  So does $1+B revenue finally translate to the 3x or more SP to Revenue that MRNA is showing

 Seems reasonable given the guidance NVAX provided that Q1 would approach or even surpass $1B in revenue.  The CFO commentary on COGS being incurred in Q4 bodes well that margins could benefit in Q1/Q2.  So does $1+B revenue finally translate to the 3x or more SP to Revenue that MRNA is showing

@ay8888 This company has not been transparent with us! The doses produced and doses shipped are just totally do not make any sense. IR will not answer my questions.

StatManDan

 This company has not been transparent with us! The doses produced and doses shipped are just totally do not make any sense. IR will not answer my questions.

@ay8888 i didnt know  about  the 19.2M to india

StockTwits For Android 

Bilvo

$nvax This revenue is in line with analysts target for 4-5 Bilion revenue for 2022, an at this revenue level - analysts are estimating around $200 per share.  EU and Australia/NZ were revealed in the news at $20.90 and $24. Novavax receives grants and royalties every quarter at around $200 million . Some companies use Matrix M for their products.

Paul

Brian Isaacson

StockTwits for iOS

 This revenue is in line with analysts target for 4-5 Bilion revenue for 2022, an at this revenue level - analysts are estimating around $200 per share.  EU and Australia/NZ were revealed in the news at $20.90 and $24. Novavax receives grants and royalties every quarter at around $200 million . Some companies use Matrix M for their products.

@ay8888 Look really accurate...... we need more countries to immediately approve us for booster, get 12-17 age group authorized for more shots, and approvals from Japan, USA, Israel, and S Africa.. 
 
I think we will do at least $2B in Q3 and Q4.    And should do $1.5 to $2B in Q2.....  It&#39;s possible we could do $6.5 to $7.5B if USA gets going on 110 million and approves booster faster for additional orders. 
 
Also, could get more orders now from India and end of year boosters for China.....booster.

 Look really accurate...... we need more countries to immediately approve us for booster, get 12-17 age group authorized for more shots, and approvals from Japan, USA, Israel, and S Africa.. 
 
I think we will do at least $2B in Q3 and Q4.    And should do $1.5 to $2B in Q2.....  It's possible we could do $6.5 to $7.5B if USA gets going on 110 million and approves booster faster for additional orders. 
 
Also, could get more orders now from India and end of year boosters for China.....booster.

@Bilvo  this was Jan. 2022 .. India cleared it for their use 
https://www.moneycontrol.com/news/trends/health-trends/about-1-crore-doses-of-siis-covovax-cleared-by-govt-lab-for-public-use-testing-of-bio-es-corbevax-to-begin-7902671.html

Nearly one crore doses of the newly approved Covid-19 vaccine, Covovax, have been dispatched after the final round of quality and safety checks at the Central Drugs Laboratory (CDL), News18.com has learnt. Expanding India's vaccine basket, the Drugs Controller General of India (DCGI) on December 28 had approved the Serum Institute's Covovax and Biological E's Corbevax.

Moneycontrol

About 1 crore doses of SII's Covovax cleared by govt lab for public use, testing of Bio E's Corbevax to begin

  this was Jan. 2022 .. India cleared it for their use 


@ay8888 Not so loud there.  Someone might take it wrong and begin a buying spree with some serious buying.  That&#39;s what it&#39;ll take now that most of the retail traders have lost interest.  I think we have to wait for institutional traders to begin adding to positions.  I&#39;m not sure what they are waiting on.  But sales do look good, but with unfortunately deliveries are more concerning right now.  They have to complete orders.  If I were Vanguard or Blackrock, that what&#39;s I&#39;d be watching.

 Not so loud there.  Someone might take it wrong and begin a buying spree with some serious buying.  That's what it'll take now that most of the retail traders have lost interest.  I think we have to wait for institutional traders to begin adding to positions.  I'm not sure what they are waiting on.  But sales do look good, but with unfortunately deliveries are more concerning right now.  They have to complete orders.  If I were Vanguard or Blackrock, that what's I'd be watching.

George Snodgrass

@ay8888 I hope so and some more surprises for Q1. If Serum keeps there pledge/recommitment Starting in April 1 we should have a great year with or without USFDA!

 I hope so and some more surprises for Q1. If Serum keeps there pledge/recommitment Starting in April 1 we should have a great year with or without USFDA!